Impact of bazedoxifene on endothelial health markers
NAGIOS: RODERIC FUNCIONANDO

Impact of bazedoxifene on endothelial health markers

DSpace Repository

Impact of bazedoxifene on endothelial health markers

Show simple item record

dc.contributor.advisor Cano Sánchez, Antonio
dc.contributor.advisor Gómez Gallego, Raúl
dc.contributor.advisor Tarín, Juan José
dc.contributor.author Dudenko Lozenko, Darya
dc.contributor.other Facultat de Medicina i Odontologia es_ES
dc.date.accessioned 2020-06-22T07:48:25Z
dc.date.available 2020-06-23T04:45:05Z
dc.date.issued 2020 es_ES
dc.date.submitted 30-06-2020 es_ES
dc.identifier.uri https://hdl.handle.net/10550/75152
dc.description.abstract Atherosclerosis and its most significant clinical repercussion, cardiovascular disease (CVD), is the leading cause of morbidity and mortality in postmenopausal women, with a substantial global public health impact as a consequence. Vascular endothelial dysfunction, which is potentiated by decreasing estrogen levels in the menopausal transition period, is an early hallmark of developing CVD. The action of estrogens has been widely investigated in many critical areas of atherogenesis, due to the presence of estrogen receptors in the vascular system. Estrogens can have both positive and negative effects on the vascular wall depending on the stage of atherosclerosis disease. The estrogen response is mediated by different mechanisms, involving either genomic pathways requiring ligand-activated transcription with posterior modulation of protein synthesis, or non-genomic pathways, mainly affecting enzyme activity and rapid signaling cascades. The vigorous debate surrounding the risk/benefit profile of estrogen in the development and timing of CVD in postmenopausal women is still ongoing. Evidence that the progestin component of hormone therapy increases breast cancer risk or even attenuates the potential beneficial effects of estrogens has been paralleled by a decline in the use of hormone therapy in postmenopausal women in recent years. This data, along with problems associated with long-term use of bisphosphonates, has shifted the focus of recent research to other molecules capable of activating estrogen receptors, leading to transcriptional activity in some tissues but not in others. Selective estrogen receptor modulators (SERMs) and more recently, tissue selective estrogen complex (TSEC) have been developed as alternatives to hormonal replacement therapy (HRT).Previous experimental studies have shown the capacity of estrogens and second-generation SERM raloxifene to promote endothelial cell regrowth and improve cell survival rate in the early stages of atherosclerosis disease. Clinical trials involving bazedoxifene or conjugated estrogens plus bazedoxifene have shown cardiovascular safety in healthy postmenopausal women. However, one research group working with an atherosclerotic animal model in monkeys demonstrated that therapeutic application of bazedoxifene had no effect on atherosclerosis. What is more, bazedoxifene completely impeded the antiatherosclerotic effects of estrogen treatment in the mentioned study. To date no report has been published of bazedoxifene’s effect on vascular cell proliferation and the mechanisms involved using an in vitro model.Previous experimental studies have shown the capacity of estrogens and second-generation SERM raloxifene to promote endothelial cell regrowth and improve cell survival rate in the early stages of atherosclerosis disease. Clinical trials involving bazedoxifene or conjugated estrogens plus bazedoxifene have shown cardiovascular safety in healthy postmenopausal women. However, one research group working with an atherosclerotic animal model in monkeys demonstrated that therapeutic application of bazedoxifene had no effect on atherosclerosis. What is more, bazedoxifene completely impeded the antiatherosclerotic effects of estrogen treatment in the mentioned study. To date no report has been published of bazedoxifene’s effect on vascular cell proliferation and the mechanisms involved using an in vitro model. es_ES
dc.format.extent 193 p. es_ES
dc.language.iso en es_ES
dc.subject bazedoxifene es_ES
dc.subject estradiol es_ES
dc.subject endothelium es_ES
dc.subject menopause es_ES
dc.subject proliferation es_ES
dc.title Impact of bazedoxifene on endothelial health markers es_ES
dc.type info:eu-repo/semantics/doctoralThesis es_ES
dc.subject.unesco UNESCO::CIENCIAS MÉDICAS es_ES
dc.embargo.terms 0 days es_ES

View       (20.79Mb)

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search

Browse

Statistics